GU
Fractyl Health, Inc.
GUTS · NASDAQ
$0.65 +0.81% (+$0.01)
1M -3.03%
Market Cap $109.0M
P/E Ratio -
Div. Yield -
ROE 1,625.88%
Bulios Fair Price
$0.43
33.8% downside
Current Price
$0.65
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GUTS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 120.27%
ROE 1,625.88%
ROA 128.88%
Debt
100 /100
Low Current ratio 3.15x
Debt/Equity N/A
Int. coverage N/A
Stability
28 /100
Unstable Beta 2.33x
EPS volatility 32.97%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GUTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Harith Rajagopalan
Employees
100
Headquarters
Burlington
Upcoming events
11 NOV
Earnings
Upcoming earnings report